Abstract
The oncologic pharmacy includes the sections of hematology, rheumatology, stem cell transplantation, as well as all the chemotherapy that is handled in the institution, but it does not include radiopharmacy, which is a segregated sector. Thereby, radiotherapy is not discussed in this section. The treatments interesting for pediatric oncology pharmacists are mostly those involving drugs. The standard treatment for pediatric cancer can include chemotherapy and other drugs—such as monoclonal antibodies and target therapy, stem cell transplantation, which also includes chemotherapy and other drugs, radiotherapy, surgery, and new approaches involving the immunity of the patient—such as the first chimeric antigen receptor (CAR) T-cell therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Schmidt CWP, de Menezes FG. Drug therapy and interactions in pediatric oncology: a pocket guide. Switzerland: Springer; 2017.
Schmidt CWP. Chemotherapy in neonates and infants: pharmacological oncology for children under 1 year old. Switzerland: Springer; 2018.
Cancer Research UK: Acute lymphoblastic leukaemia (ALL): Phases of treatment. http://www.cancerresearchuk.org/about-cancer/acute-lymphoblastic-leukaemia-all/treatment/phases. Accessed 14 May 2018.
National Cancer Institute: CAR T-cell therapy approved for some children and young adults with leukemia. 2017. https://www.cancer.gov/news-events/cancer-currents-blog/2017/tisagenlecleucel-fda-childhood-leukemia. Accessed 3 July 2018.
Stirrups R. CAR T-cells for relapsed B-cell ALL in children and young adults. Lancet Oncol. 2018;19(3):e144.
Norvatis: Kymriah (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriated r/r patients with large B-cell lymphoma. https://www.novartis.com/news/media-releases/kymriahr-tisagenlecleucel-first-class-car-t-therapy-from-novartis-receives-second-fda-approval-treat-appropriate-rr-patients-large-b-cell-lymphoma. Accessed 3 July 2018.
Fleischhack G, Hasan C, Graf N, Mann G, Bode U. IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial. Br J Haematol. 1998;102(3):647–55.
Niewerth D, Creutzig U, Bierings MB, Kaspers GJL. A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood. 2010;116:2205–14.
Rooij JDE, Zwaan CM, van den Heuvel-Eibrink M. Pediatric AML: from biology to clinical management. J Clin Med. 2015;4(1):127–49.
Burke MJ, Wagner JE, Cao Q, Ustun C, Verneris MR. Allogeneic hematopoietic stem cell transplantation in first remission abrogates poor outcomes associated with high-risk pediatric acute myeloid leukemia. Clinical Research. 2013. https://www.bbmt.org/article/S1083-8791(13)00144-4/pdf. Accessed 23 May 2018.
O’Hare P, Lucchini G, Cummins M, et al. Allogeneic stem cell transplantation for refractory acute myeloid leukemia in pediatric patients: the UK experience. Bone Marrow Transplant. 2017;52:825–31.
Hijiya N, Schultz KR, Metzler M, Millot F, Suttorp M. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood. 2016;127:392–9.
McClain K, Kamdar K. UpToDate: overview of Hodgkin lymphoma in children and adolescents. 2017. https://www.uptodate.com/contents/overview-of-hodgkin-lymphoma-in-children-and-adolescents. Accessed 25 May 2018.
Deffenbacher KE, Iqbal J, Sanger W, et al. Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling. Blood. 2012;119:3757–66.
American Cancer Society: Types of non-Hodgkin lymphoma. https://www.cancer.org/cancer/non-hodgkin-lymphoma/about/types-of-non-hodgkin-lymphoma.html. Accessed 28 May 2018.
Taran SJ, Taran R, Malipatil NB. Pediatric osteosarcoma: an updated review. Indian J Med Paediatr Oncol. 2017;38(1):33–43.
BC Cancer Agency: Cancer drug manual. Leucovorin. http://www.bccancer.bc.ca/drug-database-site/drug%20index/leucovorin_monograph_1apr2013_formatted.pdf. Accessed 1 June 2018.
Frühwald MC, Rutkowski S. Tumors of the central nervous system in children and adolescents. Dtsch Arztebl Int. 2011;108(22):390–7.
Wilimas JA, Wilson MW, Haik BG, et al. Development of retinoblastoma programs in Central America. Pediatr Blood Cancer. 2009;53(1):42–6.
Yanik Ö, Gündüz K, Yavuz K, Taçyıldız N, Ünal E. Chemotherapy in retinoblastoma: current approaches. Turk J Ophthamol. 2015;45(6):259–67.
Perlman E, Gadd S, Arold ST, et al. MLLT1 YEATS domain mutations in clinically distinctive favourable histology Wilms tumours. Nature Communications. 2015. https://www.nature.com/articles/ncomms10013. Accessed 4 June 2018.
U.S. Department of Health and Human Services: National Cancer Institute. Wilms tumor and other childhood kidney tumors treatment (PDQ®)–health professional version. https://www.cancer.gov/types/kidney/hp/wilms-treatment-pdq. Accessed 4 June 2018.
Hiyama E. Pediatric hepatoblastoma: diagnosis and treatment. Transl Pediatr. 2014;3(4):293–9.
Aronson DC, Czauderna P, Maibach R, Perilongo G, Morland B. The treatment of hepatoblastoma: its evolution and the current status as per the SIOPEL trials. J Indian Assoc Pediatr Surg. 2014;19(4):201–7.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Schmidt, C.W.P. (2019). Diseases in Pediatric Hemato/Oncology Area and Treatments. In: Pediatric Oncologic Pharmacy. Springer, Cham. https://doi.org/10.1007/978-3-030-10988-2_2
Download citation
DOI: https://doi.org/10.1007/978-3-030-10988-2_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-10987-5
Online ISBN: 978-3-030-10988-2
eBook Packages: MedicineMedicine (R0)